www.fdanews.com/articles/176054-pfizers-bococizumab-yields-positive-results-in-phase-3
Pfizer’s Bococizumab Yields Positive Results in Phase 3
April 7, 2016
Pfizer’s bococizumab soared in a second Phase 3 study, meeting its co-primary endpoints of reducing low-density lipoprotein cholesterol at 12 weeks compared with placebo.
The SPIRE-AI study assessed the PCSK9 inhibitor in 299 patients with hyperlipidemia or mixed dyslipidemia receiving statin therapy. SPIRE-AI is the second of six studies evaluating the candidate’s lipid-lowering capabilities.
Bococizumab is not approved in any country.